Published: 2018-02-22

Differential genotypical expression of a NEDD9 in normal and tumor tissues: a possible pharmacological target

Pavan Kumar G. S., Krishna V., Prabahkar B. T.


Background: Neural precursor cell expressed developmentally down regulated-9 (NEDD9) is a scaffolding metastatic marker protein in multiple cancer types. Generally, the expression occurs during the embryonic development and depletes in adults. Expression of NEDD9 in adults leads to the progression of tumor which is sufficient for the cellular invasion. Elevated behavior of the gene mediates metastatic movement which includes protease dependent neovessel formation, invasion and migration of tumor cells from the site of origin to the distant tissues.

Methods: The current study involves the screening and elucidation of differential expression of NEDD9 in normal and tumor subtypes with various tissues of mice by immunohistochemistry.

Results: The validating approaches in the study, low expression of NEDD9 was observed in the normal tissues and predominance in the tumor subsets.

Conclusions: The experimental analysis proven that NEDD9 expression is merely associated with tumor progression and the molecular mechanism of NEDD9 is restricted in the establishment of metastatic cascade. NEDD9 association in tumor prognosis which helps in the emergence of diagnostic and therapeutic approaches.


Angiogenesis, Diverse tissues, In-vivo tumor, Immunohistochemistry metastasis, NEDD9

Full Text:



Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research. 2002 May 15;62(10):2731-5.

Thirusangu P, Vigneshwaran V, Ranganatha VL, Vijay Avin BR, Khanum SA, Mahmood R, et al. A tumouralangiogenic gateway blocker, Benzophenone-1B represses the HIF-1α nuclear translocation and its target gene activation against neoplastic progression. Biochem Pharmacol. 2017 Feb 1;125:26-40.

Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets. 2013 May;13(4):423-43.

Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013 Jan;25(1):76-84.

Desouki MM, Kallas SJ, Khabele D, Crispens MA, Hameed O, Fadare O. Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors. Int J Gynecol Pathol. 2014 May;33(3):274-81.

Yu L, Mu Y, Sa N, Wang H, Xu W. Tumor necrosis factor α induces epithelial-mesenchymal transition and promotes metastasis via NF-κB signaling pathway-mediated TWIST expression in hypopharyngeal cancer. Oncol Rep. 2014 Jan;31(1):321-7.

Chapman KB, Prendes MJ, Sternberg H, Kidd JL, Funk WD, Wagner J, West MD. COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol. 2012 Aug;8(8):1031-40.

Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem. Biophys. Res. Commun. 1992;185(3):1155-61.

Karabulut M, Alis H, Afsar CU, Karabulut S, Kocatas A, Oguz H, et al. Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. Biomed Pharmacother. 2015 Jul;73:140-6.

Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015 Aug 1;567(1):1-11.

Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013 Dec;1833(12):3481-98.

Guerrero MS, Parsons JT, Bouton AH. Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. Genes Cancer. 2012 May;3(5-6):371-81.

Morimoto K, Tanaka T. Association of NEDD9 with TGF-β-triggered epithelialmesenchymal transition and cell invasion in prostate cancer cells: implications for cancer aggressiveness. Cancer Cell and Microenvironment. 2015;2:e342.

Al-Ghorbani M, Pavankumar GS, Naveen P, Thirusangu P, Prabhakar BT, Khanum SA. Synthesis and an angiolytic role of novel piperazine-benzothiazole analogues on neovascularization, a chief tumoral parameter in neoplastic development. Bioorg Chem. 2016 Apr;65:110-7.

Prabhakar BT, Khanum SA, Shashikanth S, Salimath BP. Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo. Invest New Drugs. 2006 Nov;24(6):471-8.

Vijay Avin BR, Thirusangu P, Lakshmi Ranganatha V, Firdouse A, Prabhakar BT, Khanum SA. Synthesis and tumor inhibitory activity of novel coumarin analogs targeting angiogenesis and apoptosis. Eur J Med Chem. 2014 Mar 21;75:211-21.

Mukherjee A, Dutta S, Sanyal U. Evaluation of antitumor efficacy and toxicity of novel 6-nitro-2-(3-chloropropyl)-1H-benz[de]isoquinoline-1,3-dione in vivo in mouse. J Cancer Res Ther. 2013 Jul-Sep;9(3):442-6.

Batista AP, da Silva TG, Teixeira AA, de Medeiros PL, Teixeira VW, Alves LC, Dos Santos FA. Melatonin effect on the ultrastructure of Ehrlich ascites tumor cells, lifetime and histopathology in swiss mice. Life Sci. 2013;S0024-3205(13)00614-0.

Zabiulla, Vigneshwaran V, Bushra AB, Pavankumar GS, Prabhakar BT, Khanum SA. Design and synthesis of conjugated azo-hydrazone analogues using nanoBF(3)·SiO(2) targeting ROS homeostasis in oncogenic and vascular progression. Biomed Pharmacother. 2017 Nov;95:419-428.

Thirusangu P, Vigneshwaran V, Vijay Avin BR, Rakesh H, Vikas HM, Prabhakar BT. Scutellarein antagonizes the tumorigenesis by modulating cytokine VEGF mediated neoangiogenesis and DFF-40 actuated nucleosomal degradation. Biochem Biophys Res Commun. 2017 Feb 26;484(1):85-92.

Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, Chang DD. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000 Dec 1;60(23):6744-9.

Wang Z, Shen M, Lu P, Li X, Zhu S, Yue S. NEDD9 may regulate hepatocellular carcinoma cell metastasis by promoting epithelial-mesenchymal-transition and stemness via repressing Smad7. Oncotarget. 2017;8(1):1714-24.

Guerrero MS, Parsons JT, Bouton AH. Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. Genes and Cancer. 2012;3(5-6):371-81.

Lucas JT Jr, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 2010 Aug 5;29(31):4449-59.

Elena S, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015;567:1-11.

Singh MK, Cowell L, Seo S, O’Neill GM, Golemis EA. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell biochemistry and biophysics. 2007 May 1;48(1):54-72.

O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer research. 2007 Oct 1;67(19):8975-9.

Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo C, et al. NEDD9 promotes lung cancer metastasis through epithelial–mesenchymal transition. International Journal of Cancer. 2014 May 15;134(10):2294-304.